Heparin effect on plasma fibrinogen in the thrombophilic syndrome

Abstract

Summary: The effects of heparin were studied in a group of 42 patients with preinfarction angina (PA) and acute myocardial infarction (AMI) whose plasma fibrinogen was increased. Plasma fibrinogen was measured by the turbidimetric method in timol turbidimetric units. Statistically significant results proved that heparin reduces the plasma fibrinogen progressively over a treatment period of 6 weeks. During the first three weeks a dose of I cc (50 mg or 5000 IU) was given by intravenous injection at 6-h intervals, this was followed by a dose of 2 cc (100 mg or 10,000 IU) given by subcutaneous injection at 12-h intervals for a further three weeks. Hyperfibrinogenemia is perhaps one of the most important factors in the thrombophilic syndrome, and at the same time it is one of the fundamental physiopathological alterations observed in AMI and PA. Because heparin reduces hyperfibrinogenemia it has a beneficial effect in these diseases.

Predictors of Heparin Resistance Before Cardiovascular Operations in Adults

“…Fibrinogen is one of the heparin-binding proteins. The interaction of heparin with fibrinogen has been documented to reduce anticoagulant activity by reducing the capacity of heparin to bind to antithrombin [16][17][18]. Fibrinogen is itself the substrate of the final step in the intrinsic coagulation pathway (ie, fibrinogen to fibrin).…”